Strategy Asset Managers’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $494K | Sell |
2,271
-5
| -0.2% | -$1.11K | 0.08% | 160 |
|
|
2025
Q4 | $520K | Buy |
2,276
+331
| +17% | +$75.4K | 0.09% | 150 |
|
|
2025
Q3 | $450K | Buy |
1,945
+99
| +5% | +$20.2K | 0.08% | 153 |
|
|
2025
Q2 | $343K | Buy |
1,846
+290
| +19% | +$53.9K | 0.06% | 184 |
|
|
2025
Q1 | $326K | Buy |
1,556
+18
| +1% | +$3.5K | 0.07% | 199 |
|
|
2024
Q4 | $273K | Sell |
1,538
-105
| -6% | -$19.3K | 0.05% | 218 |
|
|
2024
Q3 | $324K | Buy |
+1,643
| New | +$307K | 0.06% | 206 |
|
|
2023
Q2 | – | Sell |
-1,885
| Closed | -$300K | – | 243 |
|
|
2023
Q1 | $300K | Sell |
1,885
-39
| -2% | -$5.96K | 0.07% | 173 |
|
|
2022
Q4 | $311K | Sell |
1,924
-98
| -5% | -$15K | 0.08% | 175 |
|
|
2022
Q3 | $271K | Buy |
+2,022
| New | +$290K | 0.07% | 185 |
|
|
2019
Q3 | – | Sell |
-5,582
| Closed | -$406K | – | 120 |
|
|
2019
Q2 | $406K | Sell |
5,582
-952
| -15% | -$74.8K | 0.12% | 106 |
|
|
2019
Q1 | $527K | Sell |
6,534
-9,507
| -59% | -$778K | 0.12% | 103 |
|
|
2018
Q4 | $1.48M | Sell |
16,041
-2,089
| -12% | -$184K | 0.36% | 67 |
|
|
2018
Q3 | $1.71M | Sell |
18,130
-29,605
| -62% | -$2.81M | 0.35% | 85 |
|
|
2018
Q2 | $4.42M | Sell |
47,735
-2,015
| -4% | -$197K | 0.93% | 35 |
|
|
2018
Q1 | $4.71M | Buy |
49,750
+26,367
| +113% | +$2.9M | 1.02% | 32 |
|
|
2017
Q4 | $2.26M | Sell |
23,383
-1,051
| -4% | -$99.1K | 0.44% | 75 |
|
|
2017
Q3 | $2.17M | Sell |
24,434
-153
| -0.6% | -$11.6K | 0.44% | 77 |
|
|
2017
Q2 | $1.78M | Buy |
24,587
+8,266
| +51% | +$556K | 0.37% | 85 |
|
|
2017
Q1 | $1.06M | Buy |
16,321
+1
| +0% | +$63 | 0.23% | 85 |
|
|
2016
Q4 | $986K | Buy |
16,320
+26
| +0.2% | +$1.59K | 0.22% | 83 |
|
|
2016
Q3 | $1.03M | Buy |
16,294
+1,556
| +11% | +$101K | 0.23% | 87 |
|
|
2016
Q2 | $912K | Buy |
14,738
+553
| +4% | +$33.7K | 0.21% | 93 |
|
|
2016
Q1 | $810K | Buy |
14,185
+1,109
| +8% | +$61.8K | 0.18% | 96 |
|
|
2015
Q4 | $775K | Buy |
13,076
+19
| +0.1% | +$1.09K | 0.18% | 91 |
|
|
2015
Q3 | $710K | Sell |
13,057
-87
| -0.7% | -$5.66K | 0.17% | 92 |
|
|
2015
Q2 | $883K | Buy |
13,144
+380
| +3% | +$24.8K | 0.2% | 86 |
|
|
2015
Q1 | $747K | Sell |
12,764
-154
| -1% | -$9.3K | 0.16% | 89 |
|
|
2014
Q4 | $845K | Buy |
12,918
+221
| +2% | +$13.9K | 0.18% | 86 |
|
|
2014
Q3 | $733K | Sell |
12,697
-553
| -4% | -$30.7K | 0.16% | 87 |
|
|
2014
Q2 | $748K | Sell |
13,250
-154
| -1% | -$8.08K | 0.16% | 79 |
|
|
2014
Q1 | $689K | Sell |
13,404
-213
| -2% | -$10.8K | 0.15% | 84 |
|
|
2013
Q4 | $719K | Buy |
13,617
+1,629
| +14% | +$80.1K | 0.16% | 82 |
|
|
2013
Q3 | $536K | Sell |
11,988
-145
| -1% | -$6.43K | 0.13% | 87 |
|
|
2013
Q2 | $502K | Buy |
+12,133
| New | +$531K | 0.12% | 89 |
|
Other funds holding ABBV
VCM
VPM
Strategy Asset Managers's ABBV Position: Q1 2026 in Review
Strategy Asset Managers reduced its AbbVie (ABBV) stake by 0.22% in Q1 2026, selling an estimated $1.11K and leaving 2,271 shares worth $494K. The position accounts for 0.08% of the portfolio, ranked #160.
Strategy Asset Managers first reported a position in ABBV in Q2 2013 and has held it in 35 quarters since. The position peaked at $4.71M in Q1 2018. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Strategy Asset Managers held 2,271 shares of AbbVie worth $494K as of Q1 2026.
- Strategy Asset Managers sold 5 AbbVie shares in Q1 2026, an estimated $1.11K.
- AbbVie made up 0.08% of Strategy Asset Managers's portfolio in Q1 2026, its #160 holding.
- Strategy Asset Managers first reported a position in AbbVie in Q2 2013 and has held it in 35 quarters since.
- Strategy Asset Managers's AbbVie position peaked at $4.71M in Q1 2018.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Strategy Asset Managers's 13F filing for Q1 2026, filed 12 May 2026.